Aviva extends Founders Factory deal to forge fintech startups

Aviva's decade-long venture studio partnership has backed 60-plus startups raising £500m, and now targets insurance AI and health tech.

By Disrupts Editorial Team Sat, 10 October 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A bright, sterile data center corridor extends into the distance, flanked by rows of server cabinets with glass doors revealing numerous blinking status lights under bright fluorescent ceiling panels and exposed cable trays.

Aviva has extended its exclusive partnership with Founders Factory, the London-based venture studio and accelerator, committing a further three years of investment to spin out startups spanning insurance, wealth, property, asset management and cybersecurity. The renewal marks one of the longest-running corporate venture studio relationships in the UK and signals that the UK's largest diversified insurer is doubling down on frontier technology as a structural growth lever rather than a side project.

The decade-long programme has already supported more than 60 companies, which have collectively raised in excess of £500 million since 2016. Notable portfolio names include Tembo, a mortgage lending platform now integrated into Aviva's workplace pension proposition, and Marrow, which connects large language model agents, including ChatGPT, Claude and Gemini, directly to insurers' pricing, underwriting and policy administration systems. Scan.com, a diagnostic imaging platform that streamlined access to medical scans, closed a £220 million investment round in September 2026.

Insurance meets AI infrastructure

The new cohort of ventures will focus explicitly on harnessing AI and frontier technologies to reshape how consumers manage financial and health risk. That framing places the programme squarely at the convergence of financial services and AI-driven health infrastructure, two sectors where capital has been accelerating simultaneously but often in separate silos.

Marrow's model is arguably the most technically significant signal in the portfolio. Bridging large language model orchestration with legacy insurance back-ends is a non-trivial infrastructure problem, and its resolution has implications that extend well beyond Aviva. If agentic AI can be plumbed reliably into underwriting and policy admin at one of the UK's largest balance sheets, the blueprint becomes replicable across the European insurance market, compressing the technology adoption cycle for mid-tier carriers who lack the in-house engineering capacity to build the same connective tissue themselves.

Capital landscape and cross-sector implications

Aviva's commitment sits within a broader pattern of incumbent financial services groups using venture studio structures to internalise disruption risk. Rather than acquiring late-stage fintechs at premium valuations, the studio model allows a balance-sheet-heavy insurer to take pre-seed positions, shape product direction from inception, and retain distribution optionality through its existing customer base of 25.3 million. With group assets under management of £479 billion as at June 2026, Aviva has both the capital and the customer data scale to give portfolio companies a structural advantage in go-to-market that pure-play venture funds cannot replicate.

The health technology dimension adds a second convergence layer. Scan.com's £220 million raise illustrates appetite from growth-stage investors for diagnostic infrastructure platforms that sit at the intersection of medtech, data and consumer access, a convergence point that sovereign wealth and crossover funds have increasingly targeted across the GCC and Southeast Asia. Aviva's presence as an anchor corporate partner accelerates clinical and regulatory credibility for these ventures in a way that a generalist VC cannot.

Henry Lane Fox, CEO of Founders Factory, noted that the programme demonstrates "what's possible when a financial services business chooses to keep innovating and moves the market forward," adding that sustained commitment alongside the right founders can consistently produce category-defining companies.

For cross-sector investors, the renewal is a data point on where incumbent insurers believe value will be created in the next cycle: not in distribution alone, but in the AI-native infrastructure layer that sits beneath underwriting, health access and wealth management. The question for rivals is whether a three-year runway is long enough to close the gap with a studio that already has a decade of iteration behind it.